Augmenix™, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications.  Augmenix, Inc.'s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers.

Augmenix's vision is to address unmet patient needs following cancer radiotherapy in a variety of organ systems by developing first-of-a-kind therapeutic products based on proprietary in-situ formed hydrogel technology.